Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD

Mario Cazzola, Kai M Beeh, David Price, Nicolas Roche

Research output: Contribution to journalArticle

25 Citations (Scopus)
4 Downloads (Pure)

Abstract

The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class (β2-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically 'ideal' profile of fast onset and prolonged duration of action in comparison with existing agents, while minimizing non-specific activity at organs outside the lungs. The move towards increasing duration of bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled corticosteroids in treating COPD. In terms of onset of action, an immediately perceived benefit in reducing dyspnea, although not definitively demonstrated, might prove useful in increasing adherence, which is very poor among patients with COPD. Once-daily administration may also be helpful in this respect. Shared decision-making between patient and physician in the choice of treatment is important in optimizing adherence and, thus, treatment effectiveness.

Original languageEnglish
Pages (from-to)68-78
Number of pages11
JournalPulmonary pharmacology & therapeutics
Volume31
Early online date26 Feb 2015
DOIs
Publication statusPublished - Apr 2015

Fingerprint

Pulmonary diseases
Bronchodilator Agents
Chronic Obstructive Pulmonary Disease
Adrenergic Agonists
Muscarinic Antagonists
Cholinergic Antagonists
Dyspnea
Decision Making
Adrenal Cortex Hormones
Decision making
Maintenance
Pharmacology
Physicians
Lung
Molecules
Therapeutics

Keywords

  • adherence
  • beta-2-adrenergic agonists
  • chronic obstructive pulmonary disease
  • long-acting bronchodilators
  • muscarinic agonists
  • onset of action

Cite this

Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD. / Cazzola, Mario; Beeh, Kai M; Price, David; Roche, Nicolas.

In: Pulmonary pharmacology & therapeutics, Vol. 31, 04.2015, p. 68-78.

Research output: Contribution to journalArticle

@article{2109e62de7bb4f61b04212b63f132535,
title = "Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD",
abstract = "The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class (β2-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically 'ideal' profile of fast onset and prolonged duration of action in comparison with existing agents, while minimizing non-specific activity at organs outside the lungs. The move towards increasing duration of bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled corticosteroids in treating COPD. In terms of onset of action, an immediately perceived benefit in reducing dyspnea, although not definitively demonstrated, might prove useful in increasing adherence, which is very poor among patients with COPD. Once-daily administration may also be helpful in this respect. Shared decision-making between patient and physician in the choice of treatment is important in optimizing adherence and, thus, treatment effectiveness.",
keywords = "adherence , beta-2-adrenergic agonists, chronic obstructive pulmonary disease , long-acting bronchodilators, muscarinic agonists, onset of action",
author = "Mario Cazzola and Beeh, {Kai M} and David Price and Nicolas Roche",
note = "Date of Aceptance: 12/02/2015 Acknowledgments The authors were assisted in the preparation of the manuscript by Sarah Filcek, a professional medical writer at CircleScience (Tytherington, UK), part of KnowledgePoint360, an Ashfield Company. This assistance was funded by Novartis Pharmaceuticals. Copyright {\circledC} 2015. Published by Elsevier Ltd.",
year = "2015",
month = "4",
doi = "10.1016/j.pupt.2015.02.007",
language = "English",
volume = "31",
pages = "68--78",
journal = "Pulmonary pharmacology & therapeutics",
issn = "1522-9629",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD

AU - Cazzola, Mario

AU - Beeh, Kai M

AU - Price, David

AU - Roche, Nicolas

N1 - Date of Aceptance: 12/02/2015 Acknowledgments The authors were assisted in the preparation of the manuscript by Sarah Filcek, a professional medical writer at CircleScience (Tytherington, UK), part of KnowledgePoint360, an Ashfield Company. This assistance was funded by Novartis Pharmaceuticals. Copyright © 2015. Published by Elsevier Ltd.

PY - 2015/4

Y1 - 2015/4

N2 - The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class (β2-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically 'ideal' profile of fast onset and prolonged duration of action in comparison with existing agents, while minimizing non-specific activity at organs outside the lungs. The move towards increasing duration of bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled corticosteroids in treating COPD. In terms of onset of action, an immediately perceived benefit in reducing dyspnea, although not definitively demonstrated, might prove useful in increasing adherence, which is very poor among patients with COPD. Once-daily administration may also be helpful in this respect. Shared decision-making between patient and physician in the choice of treatment is important in optimizing adherence and, thus, treatment effectiveness.

AB - The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary disease (COPD) vary in their pharmacological class (β2-adrenergic agonist or antimuscarinic/anticholinergic, alone or combined), durations of action and speed of onset of bronchodilator effect. In the early stages of development of a maintenance bronchodilator, the goals are to identify a molecule with the theoretically 'ideal' profile of fast onset and prolonged duration of action in comparison with existing agents, while minimizing non-specific activity at organs outside the lungs. The move towards increasing duration of bronchodilator action is generally paralleled by improved effects on clinical outcomes, and the advent of more potent agents seems likely to provide an opportunity to reduce overreliance on the use of inhaled corticosteroids in treating COPD. In terms of onset of action, an immediately perceived benefit in reducing dyspnea, although not definitively demonstrated, might prove useful in increasing adherence, which is very poor among patients with COPD. Once-daily administration may also be helpful in this respect. Shared decision-making between patient and physician in the choice of treatment is important in optimizing adherence and, thus, treatment effectiveness.

KW - adherence

KW - beta-2-adrenergic agonists

KW - chronic obstructive pulmonary disease

KW - long-acting bronchodilators

KW - muscarinic agonists

KW - onset of action

U2 - 10.1016/j.pupt.2015.02.007

DO - 10.1016/j.pupt.2015.02.007

M3 - Article

C2 - 25727846

VL - 31

SP - 68

EP - 78

JO - Pulmonary pharmacology & therapeutics

JF - Pulmonary pharmacology & therapeutics

SN - 1522-9629

ER -